← All peptides

MariTide

GIPR antagonist / GLP-1 agonist. Metabolic research.

Route
SUBQ
Typical dose range
1.4 mg to 8.4 mg
Frequency
monthly
Half-life
30 days
Cycle on / off (days)
84 / 28
Evidence grade
B

Reconstitution math

Open the pre-filled MariTide reconstitution calculator to compute syringe units per dose.

Reported Side Effects of MariTide

Effects below are summarised from peer-reviewed literature or regulatory labeling where it exists. Not medical advice. Individual responses vary.

  • Nausea, vomiting, and diarrhea, especially during dose titration DailyMed
  • Constipation and early satiety DailyMed
  • Injection-site reactions including redness and induration FDA label
  • Gallbladder-related events (cholelithiasis, cholecystitis) reported in pivotal trials NEJM
  • Risk of pancreatitis (discontinue if suspected) FDA label
  • Contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2 FDA boxed warning

Compare MariTide

How MariTide stacks up against the peers most users consider.